China Temozolomide Market Research Report 2021: Sales 2016-2020, Top Manufacturers, Price 2020-2021, Outlook 2021-2025

0

DUBLIN, March 10, 2022–(BUSINESS WIRE)–The “Chinese Temozolomide Market Investigation Report 2021-2025” report has been added to from ResearchAndMarkets.com offer.

Temozolomide is a second generation alkylating agent. It is an oral chemotherapy drug used to treat brain cancers such as adult malignant glioma and malignant melanoma. It was developed by Merck & Co., Inc.

The drug was approved to enter the Chinese market under the trade name TEMODAL in 2007. In 2020, temozolomide was included in class B medical insurance in China. There are many manufacturers in the Chinese market in 2020, among which Merck Sharp & Dohme Ltd is the main manufacturer.

According to the market research, the sales value of temozolomide in the Chinese market increased year on year from 2016 to 2019. Due to the impact of COVID-19 on the overall diagnostic and treatment services of Chinese hospitals, the sales value of temozolomide in the Chinese market The Chinese market fell to CNY 793 million in 2020, and the CAGR of temozolomide in sales value from 2016 to 2020 is 9.04%.

The analyst expects that with the relief of COVID-19, the sales value of Temozolomide in the Chinese market will experience restorative growth from 2021 to 2025. Additionally, as the incidence of primary cancer of the brain increases, other cancers can cause secondary brain cancer. .

Therefore, with the widespread use of digital electronic products and the increase in the incidence of other cancers, the incidence of brain cancer is also increasing year by year, the sales value and sales volume of Temozolomide for the treatment of brain cancer will continue to rise.

At the same time, Temozolomide has the characteristics of easily penetrating the blood-cerebrospinal barrier and having mild adverse effects. The analyst predicts that the sales value and sales volume of Temozolomide in the Chinese market may increase from 2021 to 2025.

Topics Covered:

  • The impact of COVID-19 on the Chinese temozolomide market

  • China Temozolomide Sales Value 2016-2020

  • Competitive Landscape of Chinese Temozolomide Market

  • Temozolomide Price in China

  • Temozolomide Price in China by Regions and Manufacturers

  • Analysis of factors affecting the development of the Chinese temozolomide market

  • China Temozolomide Market Outlook from 2021 to 2025

Main topics covered:

1 Relevant Concepts of Temozolomide

1.1 Indications for temozolomide

1.2 Development of Temozolomide in China

1.3 Government Approval of Temozolomide in China

1.4 The impact of COVID-19 on Temozolomide sales in China

2 China Temozolomide Sales, 2016-2020

2.1 Temozolomide Sales Value

2.1.1 Overall sales value

2.1.2 Sales Value by Region

2.2 Temozolomide Sales Volume

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 China Temozolomide Sales by Dosage Form, 2016-2020

2.3.1 Injection

2.3.2 Analysis of other dosage forms

3 Analysis of Temozolomide Key Manufacturers in China in 2020

3.1 Key Manufacturers Market Share Analysis of Temozolomide

3.1.1 Market Share Survey by Sales Value

3.1.2 Market Share Survey by Sales Volume

3.2 Merck Sharp & Dohme Ltd.

3.2.1 Company profile

3.2.2 TEMODAL (Temozolomide by Merck Sharp & Dohme Ltd) Sales in China

3.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

3.3.1 Company Profile

3.3.2 China Diqing (Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Temozolomide) Sales

3.4 Beijing Shuanglu Pharmaceutical Co., Ltd.

3.4.1 Company Profile

3.4.2 China Jiaoning (Beijing Shuanglu Pharmaceutical Co., Ltd. Temozolomide) Sales

3.5 Schering-Plough Canada

3.5.1 Company Profile

3.5.2 TEMODAL (Schering-Plough Canada’s Temozolomide) Sales in China

3.6 Jiangsu Hengrui Medicine Company Ltd.

3.6.1 Company Profile

3.6.2 Jiangsu Hengrui Medicine Company Ltd. Temozolomide Sales in China

4 Temozolomide Price for Different Manufacturers in China, 2020-2021

4.1 Merck Sharp & Dohme Ltd (TEMODAL)

4.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (Diqing)

4.3 Beijing Shuanglu Pharmaceutical Co., Ltd. (Jiaoning)

4.4 Schering-Plough Canada (TEMODAL)

4.5 Jiangsu Hengrui Medicine Company Ltd.

5 China Temozolomide Drug Market Outlook, 2021- 2025

5.1 Influencing Factors of China Temozolomide Market Development

5.1.1 The impact of COVID-19 on the Chinese Temozolomide Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

For more information on this report, visit https://www.researchandmarkets.com/r/1xm0a

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220310005687/en/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Officer
[email protected]
For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900

Share.

Comments are closed.